Pharsight

Drugs that contain Relugolix

1. Orgovyx patents expiration

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7300935 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Jan, 2025

(9 months from now)

US8058280 SUMITOMO PHARMA Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2025

(9 months from now)

US11795178 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Feb, 2024

(2 months ago)

US10350170 SUMITOMO PHARMA Solid preparation
Feb, 2036

(11 years from now)

US10449191 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US10786501 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US11583526 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

Family Patents